MAPI Research Trust provides reliable, comprehensive and up-to-date information services to research scientists, pharmaceutical companies, and governmental health agencies involved in the fields of Patient-Reported Outcomes (PRO) and Epidemiology worldwide.
Home SERVICES Databases PROLabels
PROLabels

prolabels-screenshot_02.02.2012

a unique online database on Patient-Reported Outcome claims in marketing authorizations


Patient-Reported Outcomes (PROs) are valuable endpoints used in clinical studies to assess treatment benefits from the patient perspective. PROLabels is a unique database which summarizes the PRO labeling claims granted by health authorities and published on their websites, starting with the FDA and the EMA. PROLabels can be searched by therapeutic area, type of PRO, name of PRO instrument, year of approval, etc.

The PROLabels database provides:

carre6 Easy access to information regarding PRO claims for both FDA and EMA in one location

carre6 Summary information and trends in PRO claims in the US and Europe

carre6 Researchers and manufacturers with strategic information about how competitors have differentiated their products based on PRO information

carre6 Potential guidance on designing trials in specific indications that include PRO endpoints


Go to the PROLabels website




 

To access our catalog, please click here.

New questionnaires distributed by MAPI Research Trust

ACCEPT (Chronic Treatment Acceptance Questionnaire)
MAPI SAS / Registrat MAPI (France)

ADRQL (Alzheimer Disease Related Quality of Life)
Black Betty S, Kasper Judith D and Rabins Peter V. - Johns Hopkins Medical INstitutions (USA)

Barthel Index questionnaire
The Maryland State Medical Society - MedChi (USA)

ESS (Epworth Sleepiness Scale) 
Murray W. Johns (Australia)

FIRST (Fibromyalgia Rapid Screening Tool)
Serge Perrot & Didier Bouhassira (France)

PDSS-2 (Parkinson's Disease Sleep Scale)
Ray Chaudhuri (UK) & Claudia Trenkwalder (Germany)

Skindex questionnaire 
Mary-Margaret Chren (USA)

TRIM-D and TRIM-D Device (Treatment Related Impact Measure for Diabetes)
Novo Nordisk (Denmark)